<DOC>
	<DOCNO>NCT00394628</DOCNO>
	<brief_summary>Phase 1b study , evaluate safety tolerability AQ4N treatment three different dose level . Phase 2a study , evaluate safety , tolerability , addition efficacy AQ4N treatment tolerate dose select Phase 1b .</brief_summary>
	<brief_title>AQ4N Combination With Radiotherapy Temozolomide Subjects With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically proven intracranial Glioblastoma Multiforme ( GBM ) diagnosis establish biopsy resection within 5 week prior enrollment . Cranial MRI contrast CT perform 14 day prior study entry . Subjects without measurable assessable disease eligible . Plan begin partial brain radiotherapy within 2472 hour begin AQ4N , within 35 day ( 5 week ) surgery , surgery perform , biopsy confirms GBM diagnosis . Radiation therapy must give external beam partial brian field daily fraction 2.0 Gy , plan total dose tumor 60.0 Gy 6 week . Age equal great 18 year life expectancy &gt; 10 week . Karnofsky performance status &gt; 60 . Adequate bone marrow , liver renal function ( test must perform within 14 day prior enrollment ) . Negative serum urine pregnancy test ( female childbearing potential ) . Willingness use effective contraception ( male females childbearing potential ) throughout study least 2 month study treatment . Able willing give inform consent . Previous radiotherapy brain . Previous cytotoxic drug therapy , noncytotoxic drug therapy , experimental drug therapy direct brain tumor . Subjects receive Gliadel wafer exclude . Subjects previously treat enzymeinduced antiepileptic drug ( EIAEDs ) must discontinue treatment agent ( ) great equal 2 week prior enrollment . A history primary malignancy treat curative intent complete remission least 2 year ( exempt two year limit nonmelanoma skin cancer cervical carcinoma insitu biopsy squamous intraepithelial lesion PAP smear ) . Active infection . Any significant medical illness toxicity investigator ’ opinion adequately control appropriate therapy would compromise subject ’ ability tolerate therapy . Subjects must disease obscure toxicity dangerously alter drug metabolism , e.g . congestive heart failure , moderate severe liver renal disease , cancer . Cardiac ejection fraction ( LVEF ) multiple gated acquisition scan ( MUGA ) less institutional low limit normal . Prior investigational therapy within past 28 day . Prior AQ4N therapy . Hypersensitivity AQ4N ingredient contain drug formulation . Hypersensitivity temozolomide ingredient contain drug formulation dacarbazine ( DTIC ) . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>temozolomide</keyword>
	<keyword>adjuvant temozolomide</keyword>
</DOC>